Solutions
High-performing cell lines for your most complex
biologics
Optogenetic Cell line development · Process development · Non-GMP manufacturing · Tech transfer to CDMO partners
Complex biologics routinely hit developability bottlenecks with conventional cell lines where expression is fixed — always on, at a set level. Prolific’s integrated CLD service helps resolve these expression challenges early, delivering a high-performing optogenetic cell line with dynamic control over protein expression.
The result: breakthrough titers, superior on-target quality, and a clear path to GMP manufacturing with your chosen CDMO partner.
Full CLD service from gene construct through stable clonal selection to IND-enabling Research Cell Bank (RCB)
Built for molecules that push conventional platform limits
mAbs
Boost titers and CQA control for standard and complex monoclonal antibodies.
Bispecifics & multispecifics
Balance chain expression ratios for precise multispecific stoichiometry and higher titers.
Fc fusions
Control expression timing to optimise productivity and avoid common quality issues such as aggregation.
Cytokines
Tune expression levels to manage toxicity and improve yields for notoriously difficult molecules.
Enzymes & other proteins
Programme expression strategies for complex recombinant proteins beyond antibody formats.
AAV
Coming soonTime and control expression of multiple toxic components in stable HEK producer cell lines for viral vector manufacturing.
Designed around your molecule
1. Optogenetic cell line development
Transfection, stable pool generation, and clone selection using our high-performing optogenetic host cell lines. The same workflow as conventional CLD with a fundamentally more capable host.
2. Pre-clinical material generation & analytics
Delivery of pre-clinical material from pool or clone, in-house analytics suite and downstream process development.
3. Process development & research-grade material development
Process optimisation with light-controlled expression to maximise titers and on-target quality. Includes the option to generate research-grade material for early tox studies.
4. Tech transfer to your CDMO Partner
A fully defined process package with complete documentation transferred to your chosen GMP CDMO partner for a seamless path to GMP manufacturing – with Prolific support throughout.
A differentiated manufacturing strategy that strengthens your asset
Developability roadblocks resolved early
Clear CMC path from CLD through to GMP
Strengthened asset value ahead of partnering or fundraising
